The Phase III clinical trial results of Luye Pharma’s investigational drug LY03005, designated as a “Class 1 Chemical Drug” in China, were presented at the 2022 Annual Meeting of the American ...
Shanghai, China, April 12, 2022 — Luye Pharma Group announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Marketi...
Basel, Switzerland, March 31, 2022 – Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México,...
Shanghai, China, March 21, 2022 – Luye Pharma Group announced today that its investigational drug, LY03005, has received approval from the Center for Drug Evaluation (CDE) at China's Nationa...
Hong Kong, China, March 4, 2022 — Luye Pharma Group today announced that it has filed a New Drug Application (NDA) in Hong Kong, China for Lurbinectedin, for the treatment of adult patients with meta...
Luye Pharma Group has announced a partnership between its wholly-owned subsidiary Yantai Luye Drugs Trading Co. Ltd. and Chengdu Biostar Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Beijing...
Luye Pharma Group announced on December 29 that the marketing authorization application for Goserelin Acetate Extended-release Microspheres for Injection (LY01005), an innovative formulation for the t...
Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19th Nat...
Luye Pharma will receive an upfront payment of RMB 70 million, and the total payment of this agreement is up to RMB 216 million.Gensci will include Rivastigmine Single-Day Transdermal Patches and Riva...
Luye Pharma Group today announced that Rykindo® (Risperidone Microspheres for Injection (II)), its new anti-schizophrenia drug, has been put on the latest edition of the National Reimbursement Drug Li...
TOP